Get the Stockscreener App
0.232
0.39%
0.0009
Processa Pharmaceuticals Inc stock is traded at $0.232, with a volume of 3.17M.
It is up +0.39% in the last 24 hours and up +9.23% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.2311
Open:
$0.2299
24h Volume:
3.17M
Relative Volume:
0.18
Market Cap:
$2.76M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0481
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
+9.69%
1M Performance:
+9.23%
6M Performance:
-64.69%
1Y Performance:
-86.11%
1-Day Range:
$0.222
$0.2352
1-Week Range:
$0.209
$0.2497
52-Week Range:
$0.15
$1.6677
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
7380 COCA COLA DRIVE, HANOVER
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.232 | 9.16M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
How to use Fibonacci retracement on Processa Pharmaceuticals Inc.Free Chart Breakout Buy Signal Detection - Newser
Why Processa Pharmaceuticals Inc. is moving todayPrice Movement and Market Sentiment Analysis - Newser
Processa Pharmaceuticals Reports Increased Losses Amid Strategic Developments - TipRanks
Biotech-Fintech Synergy in Capital Strategy: How Processa Pharmaceuticals' Crypto Treasury Initiative Could Reshape Shareholder Value - AInvest
Processa Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Processa Pharmaceuticals explores cryptocurrency treasury strategy By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals explores cryptocurrency treasury strategy - Investing.com India
Processa Pharmaceuticals secures strategic investment and evaluates corporate crypto treasury strategies - MarketScreener
Processa Pharmaceuticals Secures Strategic Investment and Explores Cryptocurrency Treasury Strategies for Long-Term Growth - Quiver Quantitative
Processa Pharmaceuticals Secures Strategic Investment, Evaluates Crypto Treasury Strategies - AInvest
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies - GlobeNewswire
PLBY regains Nasdaq compliance with new independent director appointment | PCSA SEC FilingForm 8-K - Stock Titan
Biotech Pioneer Processa Pharmaceuticals Embraces Crypto: Strategic Investment Meets Blockchain Innovation - Stock Titan
Real time breakdown of Processa Pharmaceuticals Inc. stock performanceLow Risk High Confidence Watchlist Builder - Newser
Chart based analysis of Processa Pharmaceuticals Inc. trendsChart Driven Entry Timing for Swing Trades - Newser
Is Processa Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Pattern Detection for Entry Confirmation - Newser
Elliott Wave Theory Predicts Pullback in Processa Pharmaceuticals Inc.Consistent Profit Pattern Recognition Tools Shared - beatles.ru
Can momentum traders help lift Processa Pharmaceuticals Inc.Free Entry Alert With Low Drawdown Strategy - Newser
Volatility clustering patterns for Processa Pharmaceuticals Inc.Chart Signal and Short-Term Forecast Tracker - Newser
Using data tools to time your Processa Pharmaceuticals Inc. exitEntry Zone Watchlist With Momentum Focus - Newser
What makes Processa Pharmaceuticals Inc. stock price move sharplyEntry Signal Generator with Risk Metrics - Newser
Is Processa Pharmaceuticals Inc. a good long term investmentExpert guidance for superior capital growth - Jammu Links News
Does Processa Pharmaceuticals Inc. stock perform well during market downturnsDiscover breakthrough investment opportunities - Jammu Links News
What are the technical indicators suggesting about Processa Pharmaceuticals Inc.Invest confidently with daily market forecasts - Jammu Links News
Should I hold or sell Processa Pharmaceuticals Inc. stock in 2025Invest smarter with expert stock recommendations - Jammu Links News
When is Processa Pharmaceuticals Inc. stock expected to show significant growthExplosive earnings growth - Jammu Links News
How does Processa Pharmaceuticals Inc. generate profit in a changing economyDiscover stocks with explosive upside potential - Jammu Links News
How does Processa Pharmaceuticals Inc. compare to its industry peersMarket-crushing profits - Jammu Links News
What institutional investors are buying Processa Pharmaceuticals Inc. stockTrack stocks with high upside potential easily - Jammu Links News
What is Processa Pharmaceuticals Inc. company’s growth strategyAccelerated financial growth - Jammu Links News
What catalysts could drive Processa Pharmaceuticals Inc. stock higher in 2025Invest in stocks with long-term growth potential - Jammu Links News
What drives Processa Pharmaceuticals Inc. stock priceBuild wealth steadily with proven investment techniques - Jammu Links News
Multi factor analysis applied to Processa Pharmaceuticals Inc.Momentum Detection with Entry Optimization - Newser
How Processa Pharmaceuticals Inc. stock performs during market volatilityTechnical Reversal Setup with Risk Limits - Newser
What are analysts’ price targets for Processa Pharmaceuticals Inc. in the next 12 monthsReal Time Guidance For 2025 - Jammu Links News
Will Processa Pharmaceuticals Inc. outperform the marketPattern Recognition Based Market Move Prediction - Newser
How many analysts rate Processa Pharmaceuticals Inc. as a “Buy”Breakout Stocks Insights To Watch Now - jammulinksnews.com
Top Risks to Consider Before Buying Processa Pharmaceuticals Inc. StockFree Oversold Recovery Opportunity Stocks - Newser
Institutional scanner results for Processa Pharmaceuticals Inc.Intraday Movement Recap and Chart Summary - Newser
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):